Retatrutide half-life: how long does it stay in your system?

This article covers what the Phase 1 data shows about how retatrutide moves through the body, how long it lasts, and how it compares to other GLP-1 drugs.

How long does retatrutide stay in your system?

An approximately six-day half-life means concentration falls gradually over weeks. It does not mean the drug disappears after six days. In a simplified model, five half-lives leave about 3% of the reference concentration; that is not a validated clearance deadline for an individual.

Key Pharmacokinetic Numbers

Data from the Phase 1 single-ascending-dose study in healthy volunteers and the Phase 1b multiple-ascending-dose study in adults with type 2 diabetes.

How Once-Weekly Dosing Is Achieved

Fatty Diacid Conjugation

1. Protects the peptide from enzymatic degradation
2. Creates a circulating reservoir — the drug slowly releases from albumin into the free (active) form
3. Slows renal clearance — the albumin-drug complex is too large for kidney filtration
4. Provides sustained release — free retatrutide is continuously replenished from the albumin-bound pool

DPP-4 Resistance

An alpha-amino isobutyric acid (Aib) residue at position 2 makes retatrutide resistant to cleavage by the DPP-4 enzyme, which would otherwise degrade it within minutes.

Optimized Receptor Binding

An Aib residue at position 20 optimizes GIP receptor activity and the pharmacokinetic profile. Alpha-methyl-L-leucine at position 13 contributes to glucagon and GIP receptor activity.

Absorption and Distribution

In the single-dose Phase 1 study, peak concentrations occurred 12–72 hours after injection. Pharmacokinetics appeared nearly dose proportional across the doses studied, with mean half-lives of 134–165 hours across groups. These are study averages, not a way to predict an individual’s concentration or choose a dose.

The approximately six-day half-life supported studying once-weekly administration. It does not establish a safe interval for changing doses or stopping treatment.

Metabolism and Elimination

The molecular study establishes prolonged exposure through an albumin-binding design. It does not provide a complete clinical drug-interaction profile. Peptide chemistry alone is not enough to conclude that retatrutide cannot interact with another medicine; the dedicated interaction and renal studies below address specific unanswered questions.

Half-Life Comparison: Triple vs Dual vs Single Agonist

All three drugs use fatty acid acylation to achieve albumin binding and extended half-lives suitable for once-weekly dosing. Half-life alone does not rank their weight-loss efficacy or establish that the drugs are interchangeable.

What the Phase 1 Data Showed

Phase 1 Single-Ascending-Dose Study (Coskun et al., 2022)

Forty-seven healthy volunteers received single doses. The study established the ~6-day half-life, dose-proportional pharmacokinetics, and the 12–72 hour Tmax window.

Phase 1b Multiple-Ascending-Dose Study (Urva et al., Lancet 2022)

Adults with type 2 diabetes received weekly doses over 12 weeks at 0.5 mg, 1.5 mg, 3 mg, 3/6 mg (escalating), and 3/6/9/12 mg (escalating), with placebo and dulaglutide 1.5 mg as comparators.

Key findings:

• Pharmacokinetics were dose proportional
• Steady-state exposures were maintained with once-weekly dosing
• Body weight reduction was dose-dependent: up to -8.96 kg in the highest dose group vs placebo at 12 weeks
• HbA1c reductions of -0.4% to -1.2% across dose groups
• Safety profile consistent with other incretin drugs (GI adverse events most common)

Drug Interactions and Kidney Function: What Has Been Studied

The metoprolol interaction study

Study J1I-MC-GZQE (NCT06808802) is an open-label, single-arm, within-participant comparison. Participants took a single oral dose of metoprolol, waited a one-week washout, then received subcutaneous retatrutide followed by a second oral dose of metoprolol. Metoprolol exposure — area under the concentration curve from time zero to infinity, and maximum concentration — was measured across days 1–3 and again across days 9–11, to compare exposure before and after retatrutide in the same participants. Thirty overtly healthy adults enrolled; the trial completed on April 15, 2025.

The renal-impairment PK study

NCT05611957 is the study that speaks directly to this page's subject. It is a parallel-group, open-label Phase 1 trial in 29 adults split across three arms — normal renal function (eGFR of 90 mL/min or above), severe renal impairment, and end-stage renal disease — all given subcutaneous retatrutide. The primary endpoints are retatrutide's own AUC from time zero to infinity and its maximum observed concentration, sampled from predose out to 31 days. It completed on September 5, 2023, and the registry record has carried no results since.

That is the trial that would tell you whether reduced kidney function raises retatrutide exposure. The registry has no posted results, and this review did not locate a published result for that study. Its design alone cannot answer the question.

The kidney-function study

What is not known yet

All three records show no posted results. This review did not locate results for these specific studies, so this page describes their designs without claiming what they found. If you take other medications or have kidney disease, that is a conversation for the clinician managing it, not something to infer from a trial design.

Frequently Asked Questions

Sources

• Coskun, T., et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss. Cell Metabolism. DOI: 10.1016/j.cmet.2022.07.013.
• Urva, S., et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. DOI: 10.1016/S0140-6736(22)02033-5.
• Min, T., et al. (2025). A comprehensive review on the pharmacokinetics and drug-drug interactions of GLP-1 receptor agonists. Drug Design, Development and Therapy. DovePress.
• ClinicalTrials.gov. NCT06808802 — A Phase 1, Open-label, Single-arm Study to Investigate the Effect of Retatrutide on Metoprolol Pharmacokinetics in Healthy Participants (J1I-MC-GZQE). Completed; 30 participants; record last updated June 5, 2025.
• ClinicalTrials.gov. NCT05611957 — A Parallel-group, Phase 1, Open-label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Renal Impairment Compared With Healthy Participants. Completed September 5, 2023; 29 participants; record last updated October 2, 2023.
• ClinicalTrials.gov. NCT05936151 — A Phase 2b, Double-Blind Study to Investigate the Effect of Retatrutide on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes. Primary completion October 1, 2025; 146 participants; record last updated November 25, 2025.